Clinical Trials

Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 44
  • Start Date: December 15, 2021
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy in Elderly, Frail Newly Diagnosed Myeloma (MMY2035)
Clinical Trial
  • Status: Not yet recruiting
  • Phase: N/A
  • Intervention Type: Behavioral
  • Participants: 40
  • Start Date: December 2021
Mycobiome Supporting Diet (MSD) to Reduce Gastrointestinal (GI) Toxicity Associated With Autologous Stem Cell Transplant (ASCT) For Patients With Multiple Myeloma (MM)
Search for trials
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 1
  • Intervention Type: Biological
  • Participants: 30
  • Start Date: December 1, 2021
An Open Label, Phase 1 Study Evaluating the Activity of Modular CAR T for mYeloma
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 90
  • Start Date: November 6, 2021
Selinexor in Combination With Immunomodulator to Treat Relapsed/Refractory Multiple Myeloma Patients
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Drug, Biological
  • Participants: 37
  • Start Date: November 6, 2021
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone (Isa-KPd) for Patients With Relapsed/Refractory Multiple Myeloma
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Early Phase 1
  • Intervention Type: Biological
  • Participants: 18
  • Start Date: October 2021
A Pilot Study of Dendritic Cell DKK1 Vaccine for Patients With Monoclonal Gammopathy and Stable or Smoldering Myeloma
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 3
  • Intervention Type: Procedure, Drug
  • Participants: 716
  • Start Date: September 1, 2021
MInimal Residual Disease Adapted Strategy: Frontline Therapy for Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years; a Prospective Study
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 25
  • Start Date: September 2021
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 41
  • Start Date: September 1, 2021
A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Induction in Transplant-Eligible Multiple Myeloma Patients
Clinical Trial
  • Status: Not yet recruiting
  • Participants: 160
  • Start Date: September 2021
Covid-19 Vaccine Responsiveness in Patients With Multiple Myeloma and Waldenstrom's Macroglobulinemia
Showing 1-12 of 927